Pyxis Oncology (PYXS) Preferred Stock Liabilities (2020 - 2021)
Pyxis Oncology (PYXS) posted quarterly Preferred Stock Liabilities of $172.1 million for Q3 2021, up 684.25% year-over-year from $21.9 million in Q3 2020, and little changed quarter-over-quarter from $172.1 million in Q2 2021.
Pyxis Oncology (PYXS) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Pyxis Oncology (PYXS) has reported Preferred Stock Liabilities for 2 consecutive years, with $172.1 million the latest figure, recorded in Q3 2021.
- In Q3 2021, Preferred Stock Liabilities rose 684.25% year-over-year to $172.1 million; the TTM figure through Sep 2021 stood at $172.1 million (up 684.25% YoY), while the FY2020 annual figure was $21.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $172.1 million in Q3 2021 per PYXS's latest filing, from $172.1 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $172.1 million in Q2 2021 and bottomed at $21.9 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 172.08 Mn |
| Jun 30, 2021 | 172.08 Mn |
| Mar 31, 2021 | 21.94 Mn |
| Dec 31, 2020 | 21.94 Mn |
| Sep 30, 2020 | 21.94 Mn |